Stocks to Watch Thursday, Nov. 12: AEVEX, CuriosityStream, OptimizeRx, Capricor, B&G Foods

By Tech & Money Press · Pre-market watchlist for Thursday, November 12, 2026

Market Setup

Stocks bounced on Wednesday as CoreWeave’s third-quarter report lifted chip and AI names. The S&P 500 rose 1.3% to 7,619 and the Nasdaq Composite gained 1.6% to 25,466, according to Kiplinger. SPY closed at $759.81 (+1.3%), QQQ at $690.38 (+2.3%) and IWM at $283.09 (+0.9%), per Webull. The bond market was closed for Veterans Day. After the bell, Nvidia fell about 8.6% to roughly $158.85 in after-hours trading after The Wall Street Journal reported that its board is preparing to remove CEO Jensen Huang (our coverage), so expect chip stocks to be in focus at the open.

Thursday’s list has two after-hours earnings gainers (AEVEX and CuriosityStream), one after-hours earnings decliner (OptimizeRx) and two stocks that ran on heavy volume during Wednesday’s session (Capricor and B&G Foods). The levels below are prior highs and lows taken from real daily bars. They are reference points, not trade signals.

1. AEVEX (AVEX) – Revenue up 56% and a higher outlook, up 12% after hours

Close: $12.13 (+4.6%) · Day range: $11.50–$12.30 · Volume: about 2.2M · After hours: ~$13.61 (+12.2%), high $14.42, about 266K shares

The defense-technology company, which went public in April, reported third-quarter revenue of $189.7 million, up 56.5% from a year ago and above the roughly $149.4 million analysts expected, according to Benzinga. It posted a loss of 40 cents per share, versus expectations for a small profit. AEVEX raised its full-year 2026 revenue outlook to $820 million–$840 million, from $700 million–$720 million, and guided for adjusted EBITDA of $128 million–$132 million. A day earlier it announced an unmanned-aircraft contract with a ceiling of nearly $400 million from a U.S. customer. The company is worth about $1.5 billion.

Our Take: The revenue beat and the bigger outlook are the headline, but context matters: the stock fell about 32% on Oct. 21, from $14.34 to $9.68, after a Bloomberg report that the Navy had halted drone-boat orders, a report AEVEX disputed. The after-hours move took the stock back toward that area. Levels on the chart: $14.42 (after-hours high) and $15.03 (Oct. 20 high, the last session before the drop) above; $13.73 (Oct. 29 high) and $12.30 (Wednesday’s high) below. After-hours volume was moderate, so pre-market volume will show how much interest carries into Thursday.

2. CuriosityStream (CURI) – Back to a profit on AI licensing, up 16% after hours

Close: $2.37 (−1.7%) · Day range: $2.33–$2.46 · Volume: about 1.7M · After hours: ~$2.76 (+16.5%), high $2.81, about 554K shares

The factual-streaming company reported third-quarter revenue of $21 million, up 13% from $18.4 million a year ago, and net income of $4.8 million, compared with a $3.7 million loss. Licensing revenue rose 35% to $11.7 million, with more than $7 million from cash licensing agreements led by AI licensing deals with large language model developers, according to Benzinga’s summary of the earnings call. Adjusted EBITDA grew 67% to $5 million, the seventh straight positive quarter. CuriosityStream raised its 2026 revenue outlook to $79 million–$82 million, from $77 million–$82 million, and expects adjusted EBITDA of $20 million–$22 million. The company is worth about $141 million.

Our Take: Selling its video library to AI developers is turning into a real revenue line, and that is the story investors reacted to. Subscription revenue slipped, though, so the licensing deals are doing the heavy lifting. Levels on the chart: $2.92 (Oct. 22 high) and $3.14 (Sept. 25 high) above; $2.74 (Nov. 4 high) and $2.46 (Wednesday’s high) below. After-hours volume of about 554K shares was a third of the full regular session, which is solid interest for a stock this size.

3. OptimizeRx (OPRX) – Beat on the quarter, cut the outlook, down 20% after hours

Close: $8.95 (−4.3%) · Day range: $8.85–$9.83 · Volume: about 388K · After hours: ~$7.15 (−20.1%), low $6.88, about 34K shares

The healthcare-marketing technology company reported third-quarter revenue of $21.6 million, down 17% from $26.1 million a year ago but slightly above the $21.55 million consensus, according to Investing.com. Adjusted EBITDA rose to $6.3 million from $5.1 million, and net income was $1.2 million. The problem was the outlook: OptimizeRx lowered its 2026 revenue guidance to $87 million–$93 million, while keeping adjusted EBITDA guidance at $21 million–$25 million. CEO Stephen Silvestro said in-year contracted revenue is tracking below last year, but contracted revenue for 2027 is running ahead. The company is worth about $169 million.

Our Take: Margins are improving, but the market is pricing the revenue cut first. Note that after-hours volume was thin, about 34,000 shares, so the −20% print rests on light trading. Levels on the chart: $7.82 (Sept. 29 low) and $8.85 (Wednesday’s low) above; $7.13 (Sept. 21 low) and $6.86 (Sept. 10 low) below. The after-hours low of $6.88 sits right on that September level.

4. Capricor Therapeutics (CAPR) – Up 26% with an FDA decision due Nov. 22

Close: $11.22 (+26.5%) · Day range: $8.98–$11.23 · Volume: about 10.0M, versus about 4.5M on Tuesday · After hours: ~$11.10 (−1.1%)

The biotech closed one cent below its high, at its highest close since late July. The FDA is reviewing Capricor’s Biologics License Application for deramiocel, a cell therapy for Duchenne muscular dystrophy, with a target decision date of Nov. 22, 2026. A major amendment submitted in August added two-year open-label extension data, according to the company’s earnings call. The company reported a third-quarter net loss of $42.7 million and about $198.5 million in cash. Late in Wednesday’s session, JonesTrading upgraded the stock, according to Benzinga. The company is worth about $650 million.

Our Take: This is an event-driven stock. The run-up into a fixed FDA date can reverse quickly either way when the decision lands, and the stock has nearly doubled from its late-October low of $5.67. Levels on the chart: $11.23 (Wednesday’s high) above; $10.72 (Sept. 30 high), $10.06 (Tuesday’s high) and $8.98 (Wednesday’s low) below.

5. B&G Foods (BGS) – Up 38% on more than five times Tuesday’s volume after a beat-and-raise

Close: $3.67 (+38.0%) · Day range: $3.02–$3.67 · Volume: about 14.6M, versus about 2.7M on Tuesday · After hours: ~$3.69 (+0.5%)

The packaged-foods company reported third-quarter results Tuesday evening. Net sales rose 4.7% to $459.8 million, above the $432.3 million analysts expected, and adjusted earnings were 21 cents per share versus 15 cents expected, according to Investing.com. Base-business sales grew 5.0%, driven by a 6.1% increase in volume, according to the company’s release. B&G raised its 2026 net sales guidance to $1.76 billion–$1.80 billion and its adjusted EBITDA guidance to $280 million–$290 million. The company is worth about $298 million.

Our Take: Volume growth in a slow-growth category is what stood out. The balance sheet is still the risk: management said seasonal leverage was just over 6.4 times, according to Investing.com. The stock closed at its high of the day. Levels on the chart: $3.67 (Wednesday’s high and close) above; $3.02 (Wednesday’s low) and $2.69 (Tuesday’s high) below.

Bottom Line

AEVEX and CuriosityStream both raised their outlooks and drew real after-hours volume. OptimizeRx is the only decliner on the list, and its after-hours move came on thin trading. Capricor is about the FDA date on Nov. 22, and B&G Foods already made its move during Wednesday’s session. With Nvidia sliding after hours, broader market direction at the open may matter as much as company news. Pre-market volume is the first thing to check on each name.

Disclaimer: This article is for news and educational purposes only and is not financial advice. Price levels are shown as reference points from past trading, not as recommendations to buy or sell. Tech & Money Press is not a registered investment advisor. Trading stocks involves risk, including the loss of your investment. Do your own research and consult a licensed professional before making any investment decisions. For news and education only. Not financial advice.

Sources: Price data from Webull (regular-session bars; after-hours prices as of about 7:55 p.m. ET, Nov. 11, 2026). Company news and earnings via Benzinga, company press releases (GlobeNewswire, SEC filings), Investing.com and The Motley Fool. Market figures via Kiplinger.